OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
OS Therapies IncorporatedAMEX: OSTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 30783.5% from a year ago
Cash & equivalents stood at $917.55M at the end of Q1 FY2026, up 30783.5% from a year earlier and up 240.0% from the prior quarter. Over 3 fiscal years it compounded at +1063.1% a year.
Context
- Cash & equivalents amounted to 12570.5% of total assets at the end of Q1 FY2026, up 12500.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +30783.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 269.83M USD
- Year-over-year change
- +4776.3%
- 4-year CAGR
- +660.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 269.83M | +4776.3% |
| FY2024 | 2024-12-31 | 5.53M | +14095.1% |
| FY2023 | 2023-12-31 | 38.98K | -77.3% |
| FY2022 | 2022-12-31 | 171.48K | +112.3% |
| FY2021 | 2021-12-31 | 80.79K | — |
Cash & Equivalents vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's Mar 2026 cash & equivalents of $917.55M is the highest of the 9 companies compared; the peer median is $15.76M.
- Its year-over-year change of +30783.5% is the highest of 9, against a peer median of +21.5%.
- Cash & equivalents amounts to 12570.5% of total assets for OSTX, versus a peer median of 91.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | Mar 2026 | $917.55M | +30783.5% | +1063.1% | 12570.5% |
| Dec 2025 | $74.52M | -12.5% | -19.7% | 95.2% | |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Jun 2026 | $21.99M | -71.7% | -23.5% | 91.0% | |
| Mar 2026 | $9.53M | +194.5% | -12.0% | 91.8% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding OSTX) | $15.76M | +21.5% | -19.8% | 91.4% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 80.79K | 171.48K | 38.98K | 5.53M | 269.83M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 231.07K | 1.15K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 956K | 324.21K | 751.05K | 0 | (269.56M) |
| Total Current Assets | 312.82K | 496.84K | 790.03K | 5.53M | 332.91K |
| Property, Plant & Equipment (Net) | 13.08K | 12.27K | 8.05K | 5.27K | 2.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 6.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | (0) | (2.49M) |
| Total Non-current Assets | 13.08K | 12.27K | 8.05K | 5.27K | 6.51M |
| Total Assets | 325.89K | 509.11K | 798.08K | 5.54M | 6.84M |
| Account Payables | 856.52K | 1.23M | 2.72M | 1.66M | 9.94M |
| Short-term Debt | 0 | 0 | 14.61M | 0 | 0 |
| Tax Payables | 367.02K | 426.01K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.61M | 3.04M | 4.71M | 2.35M | 0 |
| Total Current Liabilities | 3.5M | 6.15M | 24.71M | 4.63M | 11.76M |
| Long-term Debt | 7.07M | 10.35M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 100K | 100K | 100K | 0 | 100K |
| Other Non-current Liabilities | 1.11M | 1.47M | 100K | 100K | 1.07M |
| Total Non-current Liabilities | 8.28M | 11.92M | 100K | 100K | 1.17M |
| Total Liabilities | 11.78M | 18.07M | 24.81M | 4.73M | 12.94M |
| Common Stock | 9.98K | 4.99K | 5.34K | 20.87K | 37.12K |
| Retained Earnings | (15.22M) | (21.6M) | (29.52M) | (40.4M) | (67.19M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (11.45M) | (17.56M) | (24.02M) | 811.49K | (6.1M) |
| Total Debt | 7.07M | 10.35M | 14.61M | 0 | 0 |
| Net Debt | 6.99M | 10.18M | 14.57M | (5.53M) | (269.83M) |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.